title: A phase II study of pegylated liposomal doxorubicin oxaliplatin and cyclophosphamide as second-line treatment in relapsed ovarian carcinoma.
abstract: We carried out a phase II nonrandomized study to examine the level of activity of oxaliplatin, pegylated liposomal doxorubicin, and cyclophosphamide in a patient population with relapsed ovarian cancer pretreated with platinum derivatives and paclitaxel. Patients received oxaliplatin (85 mg/m2), pegylated liposomal doxorubicin (30 mg/m2), and cyclophosphamide (750 mg/m2). A total of 49 patients (39 assessable for toxicity and response) were enrolled in this trial. Neutropenia grade 3 was observed in six patients (15%) and anemia grade 3 in one patient (0.2%). Fatigue grade 1-2 occurred in 26 patients (66%), nausea/vomiting grade 1 in 23 patients (58%), and alopecia grade 1-2 in 19 patients (48%). Twenty-one (53%) patients experienced grade 1-2 peripheral neuropathy. The overall response rate was 46% (95% CI 23.6-68.7). Median progression-free survival was 28 weeks (range 12-52 weeks) and median survival was 45 weeks (range 26-136+ weeks). The mean duration of response was 34 weeks (range 16-52 weeks). In platinum-resistant and -refractory ovarian cancer patients, the overall response rate was 37% (CI 95% 14.4-60.8) with a progression-free survival of 28 weeks (range 12-52 weeks) and a median survival of 42 weeks (range 28-84 weeks). This combination chemotherapy is generally well tolerated and is an active second-line regimen against ovarian cancer.
authors.affiliation: Operative Unit of Medical Oncology, Department of Oncology, Università degli Studi di Palermo, Palermo, Italy.
authors.forename: M R
authors.initials: MR
authors.lastname: Valerio
authors.forename: P
authors.initials: P
authors.lastname: Tagliaferri
authors.forename: F
authors.initials: F
authors.lastname: Raspagliesi
authors.forename: F
authors.initials: F
authors.lastname: Fulfaro
authors.forename: G
authors.initials: G
authors.lastname: Badalamenti
authors.forename: C
authors.initials: C
authors.lastname: Arcara
authors.forename: G
authors.initials: G
authors.lastname: Cicero
authors.forename: A
authors.initials: A
authors.lastname: Russo
authors.forename: S
authors.initials: S
authors.lastname: Venuta
authors.forename: G
authors.initials: G
authors.lastname: Guarneri
authors.forename: N
authors.initials: N
authors.lastname: Gebbia
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D000077150:Oxaliplatin; D011092:Polyethylene Glycols / Q000008:administration & dosage; D016019:Survival Analysis
chemical_list: D009944:Organoplatinum Compounds; C506643:liposomal doxorubicin; D000077150:Oxaliplatin; D011092:Polyethylene Glycols; D004317:Doxorubicin; D003520:Cyclophosphamide